TRP_1170x120_3-8-19

rheumatoid arthritis

FDA recommends the approval of Baricitinib 2mg

FDA recommends the approval of Baricitinib 2mg

INDIANAPOLIS — Eli Lilly and Incyte Corp.  announced that the U.S. Food and Drug Administration’s (FDA) Arthritis Advisory Committee recommended approval of the 2-mg dose of baricitinib, a once-daily oral medication for the treatment of moderately-to-severely active rheumatoid arthritis (RA) for adult patients who have had an inadequate response or intolerance to methotrexate. While the

CVS Health launches Transform Rheumatoid Arthritis Care

CVS Health launches Transform Rheumatoid Arthritis Care

WOONSOCKET, R.I. — CVS Health has added a rheumatoid arthritis program to its Transform Care offering to help pharmacy benefit management clients better manage care and costs for certain disease states. Called Transform Rheumatoid Arthritis Care, the new program aims to foster the use of lower-cost therapies via pharmacy network and utilization management tools, along with value-based